Asensus Surgical, Inc. Announces Sapporo Medical University Hospital in Japan to Initiate Senhance Robotic Surgery Program
29 Setembro 2021 - 9:00AM
Business Wire
Sapporo Medical University Hospital to become 5th Senhance
hospital in Japan
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced Sapporo Medical University Hospital, located in
Hokkaido, Japan, has entered into an agreement to lease and utilize
a Senhance® Surgical System.
“The Department of Surgery, Surgical Oncology and Science at
Sapporo Medical University Hospital is an outstanding institution
which is well known for utilizing the most advanced surgical
technologies, and we are very excited to partner with them to
expand their existing surgical robotics program,” said Anthony
Fernando, Asensus Surgical President and CEO. “Japan remains a
focus market for Senhance. With a dedicated training center and a
growing number of active systems at prestigious institutions, we
expect to further accelerate adoption in the region in the
future.’’
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform that
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3 mm instruments
(the smallest instrument available in the world on a robotic
surgical platform). The Senhance Surgical System is powered by the
Intelligent Surgical Unit™ (ISU™). The ISU enables machine
vision-driven control of the camera for a surgeon by responding to
commands and recognizing certain objects and locations in the
surgical field, and allows a surgeon to change the visualized field
of view using the movement of their instruments.
“We are highly focused on integrating state-of-the-art medical
technologies into our hospital to provide our patients with the
best possible outcomes,” said Professor Dr. Ichiro Takemasa,
Chairman of Surgical Oncology and Science. “We have run a
successful robotics program at Sapporo for a number of years, and
believe the Senhance is a great addition to that program which will
expand the scope of procedures in which we can utilize robotics
with and brings incremental surgical intelligence that we don’t
have access to with our other systems.’’
About Sapporo Medical University Hospital
Sapporo Medical University Hospital has facilities in 29
clinical divisions and 932 inpatient beds. It provides advanced,
state-of-the-art medical care, such as emergency medical care,
cancer treatment and regenerative medicine, and also plays a
significant role as a medical institution that assists the
development of local medical services and accepts patients from
remote areas in Hokkaido in cases of disasters. In 1996, the
hospital was certified as an advanced treatment facility capable of
providing advanced medical treatment, developing medical
technologies, and offering training. In 2002, Hokkaido’s first
advanced emergency medical care center was established within the
hospital to accept critical emergency patients and provide advanced
specialized medical treatment. In 2016, it was certified as the
first tour facility to perform colorectal cancer surgery by a robot
in northern Japan and has a dedicated robotic operating room. The
hospital also functions as an AIDS treatment core hospital (HIV
Hokkaido Regional Hospital), a core disaster medical hospital, the
Hokkaido Rehabilitation Support Center, and a regional cancer
center.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For more
information, visit www.asensus.com.
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and Sapporo Medical University Hospital initiating
a program with the Senhance System. These statements and other
statements regarding our future plans and goals constitute "forward
looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and are intended to qualify for the safe harbor from
liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties
that are often difficult to predict, are beyond our control and
which may cause results to differ materially from expectations and
include whether Asensus will be able to further expand its
footprint in the Asia-Pacific region and whether the Senhance
Surgical System will be a great addition to the robotics program at
Sapporo Medical University Hospital . For a discussion of the risks
and uncertainties associated with the Company’s business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2020, filed with the SEC on March 11, 2021 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210929005516/en/
INVESTOR CONTACT: Mark Klausner or Mike Vallie,
443-213-0499 invest@asensus.com or MEDIA CONTACT: Kristin
Schaeffer, 858-354-8850 CG Life kschaeffer@cglife.com
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Asensus Surgical, Inc. (NYSE:ASXC)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025